Icon
+91 94997 68112
Login Register

REVUFORJ - (EQ 25MG BASE,EQ 110MG BASE,EQ 160MG BASE ; Tablet)

REVUMENIB CITRATE SYNDAX
EQ 25MG BASE,EQ 110MG BASE,EQ 160MG BASE ; Tablet
Less Than $1000 mn
None None
None None
None None
REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.
Yes
REVUFORJ Patent 1 Patent 2
*** *********
********** ** *** *****-*** *********** ********** ** *** *****-*** ***********
  1. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. **,***,*** (*** **, ****). **** **** ********* ** *** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** *** **, ****.
  2. *** **, **** : * ****** **** ********* *** **** ***** ** ********* *** ****** **. **,***,*** (*** **, ****). **** **** ********* ** *** ****, ** **** ******** **** ** *** *** ****** ****** ***** ** *** **, ****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.